read more
read more
read more
Innovations in Biologics Discovery and Development
Date: Mar 23, 2013
Type: Association Events
Organizer: SABPA
Location: Institute of Americas, UCSD
Source: SABPA
SABPA Sci&Tech Forum 2013 Agenda 012413 WL.pdf
SABPA_Sci&Tech Forum 2013 Brochure.pdf

Innovations in Biologics Discovery and Development


Date:                March 23, 2013, Saturday, 8:30am To 3:00pm (Lunch will be provided)

Location:         Institute of Americas, UCSD

                         (Direction available at

Registration:  Closed

         $20 for online registration, $10 for students and post-docs.  $40 for on-site registration,

         Online registration ends March 21, 2013

Please see attachement for brochure. 


For the past two decades, biologics have revolutionized the treatment of diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis, and are widely used in treating a variety of cancers.  Biologics is a rapidly developing field of therapeutics and there is a trend for pharmaceutical and biotech industries to drift toward biologics development due to the promise of biologic drugs.  


At the SABPA Science & Technology Forum XI, we bring together leaders in academic and pharma/biotech industry to discuss current trend in biologics discovery and development, as well as challenges facing the field. The presentations will address new technologies in discovering novel biologic therapeutics including the use of unnatural amino acids, somatic hypermutation and directed molecular evolution as well as developing biologics delivery platform.  The meeting will cover therapeutic antibodies, proteins, peptides, vaccines and therapeutic areas from cancers, autoimmune to cardiovascular diseases.


Event Program



Registration & Breakfast


Opening Remarks


Chairperson of session 1


Peter Schultz, Ph.D.

Professor of Chemistry, Scripps Research Institute; and Director of California Institute for Biomedical Research 

Title:  A Chemist's Foray into Translational Medicine.


Thomas F Bumol, Ph.D.

Vice President of Biotechnology and Autoimmunity, Lilly Research Laboratories, Lilly Biotechnology Center-San Diego

Title: Biotechnology as a Sustainable Source of Pharmaceutical Innovation: the Lilly Biotechnology Strategy.


David King, Ph.D.

Chief Scientific Officer, AnaptysBio Inc

Title: Generating Improved Antibody Therapeutics through Somatic Hypermutation in vitro


Refreshment Break, Exhibit & Networking


Chairperson of session 2


Jeremy Barton, MD.

Vice President, Biotherapeutics Development, Pfizer

Title: Antibody Drug Conjugates: Blockbusters of the Next Decade?


Henry Ji, Ph.D.

Chief Executive Officer and President, Sorrento Therapeutics

Title: The G-MAB®Library Technology – Discovery and Development of New Human Therapeutic Antibodies


Panel Discussion: Biologics Development


Steve Prestrelski, Ph.D., M.B.A.

Chief Scientific Officer, Xeris Pharmaceuticals, Inc.


1. Bhawanjit Brar, Ph.D., Senior Director, Zensun USA

2. Jean I Liu, M.S., J.D., Vice President, General Counsel and Secretary, Halozyme Therapeutics, Inc.

3. Brenden S. Gingrich, Ph.D., J.D., Partner, Knobbe Martens

4. Tim Tian, Ph.D., Senior Scientist, Laureate BioPharma

5. Olivier Laurent, Ph.D., Director, Protein Science, CovX


Closing Remarks:




Platinum Corporate Sponsors:

Gold Corporate Sponsors

Silver Corporate Sponsors:

Bronze Corporate Sponsors:

Platinum Event Sponsors

Gold Event Sponsors

Silver Event Sponsors

Bronze Event Sponsors: